Projects funded by the NCN


Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Search results

21 projects found matching your search criteria :

  1. Lyn tyrosine kinase as regulator of lipopolysaccharide-triggered TLR4 pro-inflammatory signaling

    Call: PRELUDIUM 7 , Panel: NZ3

    Principal investigator: dr Kinga Borzęcka-Solarz

    Instytut Biologii Doświadczalnej im. M. Nenckiego PAN

  2. Inhibition of p21-Activated Kinase (PAK) as a new molecular target in the treatment of chronic myeloid leukemia (CML)

    Call: OPUS 6 , Panel: NZ7

    Principal investigator: dr hab. Sylwia Flis

    Narodowy Instytut Leków

  3. Mechanism regulating vitamin D analog cooperation with cytostatics and tyrosine kinase inhibitors in non-small cell lung...

    Call: PRELUDIUM 5 , Panel: NZ4

    Principal investigator: dr Ewa Maj

    Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda PAN

  4. Polymorphic pre-miR-146a and synergistic action of all of its products on NTRK2 gene in Papillary Thyroid Carcinoma

    Call: PRELUDIUM 4 , Panel: NZ2

    Principal investigator: dr Anna Kubiak

    Warszawski Uniwersytet Medyczny, I Wydział Lekarski

  5. Zn2+-dependent competition between CD4 and CD8α coreceprtor for Lck tyrosine kinase

    Call: SONATA 19 , Panel: NZ1

    Principal investigator: dr Anna Kocyła

    Uniwersytet Wrocławski, Wydział Biotechnologii

  6. Novel aspects of the mechanisms of vascular toxicity of tyrosine kinase inhibitors: studies on their proinflammatory act...

    Call: OPUS 26 , Panel: NZ5

    Principal investigator: dr Tomasz Prajsnar

    Uniwersytet Jagielloński, Wydział Biologii

  7. Investigating the mechanisms of CD20 downregulation triggered by tyrosine kinase inhibitors in Philadelphia chromosome-p...

    Call: PRELUDIUM 22 , Panel: NZ5

    Principal investigator: Krzysztof Domka

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego Polskiej Akademii Nauk

  8. INVADOPODIA IN AXL-DRIVEN CANCER INVASION AND DRUG RESISTANCE

    Call: OPUS 25 , Panel: NZ3

    Principal investigator: dr Daria Zdżalik-Bielecka

    Uniwersytet Warszawski, Wydział Biologii

  9. Effects of tyrosine kinase inhibitors on Syk pathway in eNOS-based platelet subpopulations and on endothelial barrier in...

    Call: POLONEZ BIS 3 , Panel: NZ7

    Principal investigator: dr hab. Aneta Radziwon-Balicka

    Uniwersytet Jagielloński, Jagiellońskie Centrum Rozwoju Leków (JCET)

  10. New strategies in the treatment of non-small cell lung cancer based on silk nanocarriers targeting tumor vascularization

    Call: SONATA 17 , Panel: NZ7

    Principal investigator: dr Anna Florczak

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  11. RE-SENSE: Dual-loaded lipid nanoparticles to overcome the resistance of non-small cell lung cancer cells to personalized...

    Call: PRELUDIUM 20 , Panel: NZ7

    Principal investigator: Mikołaj Czajkowski

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  12. AXL receptor signaling in cancer cell growth and drug resistance

    Call: OPUS 20 , Panel: NZ3

    Principal investigator: prof. Marta Miączyńska

    Międzynarodowy Instytut Biologii Molekularnej i Komórkowej w Warszawie

  13. Iron chelators as tyrosine kinase inhibitors - a new strategy for the treatment of glioblastoma multiforme

    Call: PRELUDIUM BIS 2 , Panel: NZ5

    Principal investigator: dr hab. Anna Mrozek-Wilczkiewicz

    Uniwersytet Śląski w Katowicach, Wydział Nauk Ścisłych i Technicznych

  14. A novel approach based on the optimized multidrug combination for glioblastoma treatment.

    Call: SONATA 16 , Panel: NZ7

    Principal investigator: dr Małgorzata Kucińska

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  15. Comparative evaluation of effects of tyrosine kinase inhibitors (TKIs) on endothelial function in vivo in mice

    Call: PRELUDIUM 17 , Panel: NZ5

    Principal investigator: Brygida Marczyk

    Uniwersytet Jagielloński, Jagiellońskie Centrum Rozwoju Leków (JCET)

  16. Insights into biological activity and mechanism of action of novel styrylquinazoline derivatives as tyrosine kinase inhi...

    Call: PRELUDIUM 12 , Panel: NZ7

    Principal investigator: Katarzyna Malarz

    Uniwersytet Śląski w Katowicach, Wydział Matematyki, Fizyki i Chemii

  17. Impact of palmitoylation on the Zn(II)-dependent interaction between CD4 coreceptor and Lck tyrosine kinase.

    Call: PRELUDIUM 11 , Panel: NZ1

    Principal investigator: Anna Kocyła

    Uniwersytet Wrocławski, Wydział Biotechnologii

  18. Analysis of the effectiveness of anticancer activity of tyrosine kinase inhibitors combined with nanoparticles in in vit...

    Call: SONATA 11 , Panel: ST4

    Principal investigator: dr Natalia Piergies

    Instytut Fizyki Jądrowej im. Henryka Niewodniczańskiego Polskiej Akademii Nauk

  19. Endocytosis of AXL receptor and its role in AXL-mediated signaling.

    Call: SONATA 10 , Panel: NZ3

    Principal investigator: dr Daria Zdżalik-Bielecka

    Międzynarodowy Instytut Biologii Molekularnej i Komórkowej

  20. New MOF compounds as degradable nanocontainers of tyrosine kinases inhibitors in novel anti-cancer therapy

    Call: OPUS 9 , Panel: ST5

    Principal investigator: prof. Artur Terzyk

    Uniwersytet Mikołaja Kopernika, Wydział Chemii

  21. Protein and gene expression analysis in the course of renal cancer stem-like cells' primary resistance to sorafenib in h...

    Call: PRELUDIUM 9 , Panel: NZ5

    Principal investigator: Zofia Bielecka

    Wojskowy Instytut Medyczny